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Study design {#sec1}
============

Open-label, prospective, randomized trial from Sweden (Invasive Revascularization or Not in Intermittent Claudication \[IRONIC\]) enrolled between March 2010 and November 2012.

Key findings {#sec2}
============

After 5 years, there were no differences in quality of life or treadmill walking distance for 116 patients with mild to severe claudication randomized to revascularization plus best medical therapy plus structured exercise therapy (revascularization group) vs best medical therapy plus structured exercise (nonrevascularization group) who completed the primary end point. Medical therapy included cilostazol (Pletal) in both groups. Revascularization was associated with twice the cost per patient compared with noninvasive treatment (\$13,000 vs \$7000).

Conclusion {#sec3}
==========

Revascularization lost its early benefit after 5 years and did not result in long-term improvement in quality of life or walking capacity compared with noninvasive treatment. Revascularization is not a cost-effective treatment option.

Commentary {#sec4}
==========

If the findings of this study are to be believed, we should not perform endovascular or surgical interventions for claudication. I question the conclusions of this study. If a patient undergoes endovascular therapy or an arterial bypass for disabling claudication, subsequently walks as far as he or she wants for 4 years, and then the stent or graft occludes, wouldn't the patient say the intervention greatly improved his or her quality of life for 4 years but not at 5 years? The authors admit that intervention resulted in improved quality of life at least during the first 2 years. Since the COVID-19 crisis, I have been sitting in front of my computer for many hours for many days and my lower back is killing me. If spine surgery would completely relieve my low back pain for 4 years but not 5, I think I would do it. The real question is how much intervention improved patients' quality of life *during* the 5 years after intervention, not necessarily *at* 5 years.

There are four significant weaknesses of this paper. First, the authors point out that their study targeted patients with "mild to severe" claudication. Obviously, mild claudicants will not benefit from intervention, just as patients with "mild" carotid artery disease will not benefit from carotid intervention. None of us, it is to be hoped, would offer intervention to patients with mild claudication anyway. Second, the authors excluded patients with "very severe claudication." These are patients most likely to benefit from intervention. Third, TransAtlantic Inter-Society Consensus (TASC) A to C lesions were treated only with endovascular intervention and TASC D lesions only with surgery. I question how many patients with TASC C lesions might have done better with surgery. Fourth, patients were allowed to crossover to the intervention arm after 6 months if their claudication continued to be disabling. Were these patients considered to have complete failure of conservative treatment?

I concede we should encourage smoking cessation and supervised exercise programs more than we do. But I have felt very rewarded after performing vascular intervention for claudicants who could not walk a block but who later returned for surveillance studies grateful they could walk as far as they wanted for 5 and, dare I say, even for 10 years after the intervention.
